BioMedNewsBreaks

ThursdayMay 06, 2021 3:02 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Expansion of World-Class IP Portfolio

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has entered into an amendment to a May 2020 license agreement with a major cancer research center in Houston, Texas, to grant to Genprex an exclusive worldwide license to an additional portfolio of six patents and one patent application and related technology (“newly licensed IP”). The newly licensed IP includes methods for treating non-small cell lung cancer (“NSCLC”) by administration of a TUSC2 therapeutic in conjunction with EGFR inhibitors or other anti-cancer therapies in patients predicted to…

Continue Reading

ThursdayMay 06, 2021 1:33 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) President to Present, Participate at Fifth International Vatican Conference

DarioHealth (NASDAQ: DRIO) president and North America general manager Rick Anderson will present at this year’s Vatican conference; the conference will be virtual this year. The Vatican's Pontifical Council for Culture and the Cura Foundation's Fifth International Vatican Conference is designed to globally advance human health by bringing together physicians, scientists, patient advocates, policy makers and other influential leaders from around the world. During the conference, which will be held May 6–8, 2021, participants discuss the latest breakthroughs in medicine, health care delivery and prevention. Anderson will be a featured presenter on the conference’s Insight and Perspectives track, as he discusses…

Continue Reading

WednesdayMay 05, 2021 12:15 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Centralized IRB Approval for Acclaim-1 Clinical Trial

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its receipt of centralized Institutional Review Board (“IRB”) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung cancer (“NSCLC”). Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial that combines the company’s lead drug candidate, REQORSA(TM) immunogene therapy, with AstraZeneca’s Tagrisso(R) (osimertinib) in patients with late-stage NSCLC with mutated epidermal growth factor receptors (“EGFRs”), whose disease progressed after treatment with Tagrisso. “The purpose of IRB review is to assure that appropriate steps…

Continue Reading

TuesdayMay 04, 2021 4:22 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Appoints Proven Pharmaceutical Exec as Chief Commercial Officer

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Ann Cunningham as its chief commercial officer. Cunningham, who has been and will continue serving on VTGN’s board of directors, has a proven pharmaceutical commercial track record of more than 25 years delivering sales, marketing and global life cycle product management expertise in roles across several health care markets, including neuropsychiatry and other CNS markets that VistaGen is pursuing. “Since joining our board, Ann’s…

Continue Reading

TuesdayMay 04, 2021 12:19 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Acclaim-2 Clinical Trial

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced it has commenced clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). An open-label, multicenter Phase 1/2 clinical trial, Acclaim-2 combines Genprex’s lead drug candidate, REQORSA(TM) immunogene therapy, with Merck & Co Inc.’s Keytruda in patients with late-stage NSCLC who are low expressors (1% to 49%) of the protein programmed death-ligand 1 ("PD-L1"). “Our clinical team remains focused on engaging with leading clinical investigators and esteemed research institutions in…

Continue Reading

MondayMay 03, 2021 3:21 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Eyes Significant Market Opportunity

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, raised eyebrows when it announced that XPhyto Laboratories Inc., its Alberta subsidiary, added mescaline production to its psychedelic medicine development programs earlier this year (https://ibn.fm/cHwJi). Mescaline has begun attracting legislative attention, much like was the case with cannabis, which gained widening legalization as state after state approved varied uses of hemp and cannabis within their political boundaries. Recently, California Senator Scott Wiener introduced a bill that would decriminalize select hallucinogenics, including mescaline, in part due to research from top medical universities indicating that such substances can have significant benefits…

Continue Reading

MondayMay 03, 2021 10:07 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) Announces Partnership with Leading Educational Platform to Provide Psychedelic Therapy Training

Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered a master service agreement with Fluence, an expertise-driven educational platform that provides professional training in psychedelic therapy and psychedelic integration for psychiatrists, psychotherapists, social workers, and other healthcare practitioners. The partnership will provide design and training for the psychotherapeutic component of Tryp's clinical trial activities and will strengthen Tryp's capability to plan and implement clinical trials. The agreement will also enhance the company’s ability to make the most of the information gathered. Fluence has specific expertise in psychedelic clinical trials…

Continue Reading

FridayApr 30, 2021 12:10 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Offering Cost-Effective, Efficient BCI Solutions

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, has created two FDA-cleared products (the NeuroCap(TM) and NeuroEEG(TM)) that are nothing like other brain-computer interface (“BCI”) solutions in the market. It has been observed that “data collected from consumer-centric, low-cost BCIs are typically not as efficient or as pristine as that retrieved from research-grade conventional wired EEGs (electroencephalograms),” notes a recent article. “Many of the BCIs on the market are not gelled so that the consumer can easily fit the product themselves. They have far fewer electrodes and are designed for the ease of the…

Continue Reading

ThursdayApr 29, 2021 2:01 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Continues to Strengthen Position in Plant-Based Health Industry

Healthy Extracts (OTCQB: HYEX) is committed to growth and has aligned its operations to focus on the plant-based health industry. Reflecting this focus, HYEX changed its name from Grey Cloak Tech to align with the company’s objectives and a “Live Life Young Again” strategy. “The company is making remarkable strides to strengthen its market positions in the plant-based health industry through its two key subsidiaries, the science-based BergaMet North America and Ultimate Brain Nutrients (‘UBN’),” reads a recent article. The company also achieved significant accomplishments in 2020, including a 71% increase in recorded gross revenue, despite the COVID pandemic, as…

Continue Reading

ThursdayApr 29, 2021 1:45 pm

BioMedNewsBreaks – RYAH Group Inc. Featured in Bell2Bell Podcast

RYAH Group, engaged in the development and commercialization of various innovative technology solutions for the plant-based medical industry, was featured in The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. RYAH’s CEO Gregory Wagner joined the latest episode to discuss the company’s 2021 goals and milestones, as well as provide an overview of RYAH’s business model and product offerings. “I came to the company two years ago, and the reason why I came here from a different career was because I was completely floored by the amount of data this…

Continue Reading